WINTON GROUP Ltd Acquires Shares of 58,661 LivaNova PLC $LIVN

WINTON GROUP Ltd acquired a new stake in shares of LivaNova PLC (NASDAQ:LIVN) in the second quarter, HoldingsChannel reports. The fund acquired 58,661 shares of the company’s stock, valued at approximately $4,824,000.

Several other hedge funds also recently added to or reduced their stakes in LIVN. Allworth Financial LP grew its stake in LivaNova by 93.5% in the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. Hantz Financial Services Inc. grew its stake in LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares during the last quarter. State of Wyoming bought a new position in shares of LivaNova during the second quarter worth about $31,000. EverSource Wealth Advisors LLC grew its position in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the last quarter. Finally, Quarry LP bought a new position in LivaNova in the 3rd quarter worth approximately $36,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Down 1.0%

LIVN opened at $78.18 on Friday. The business has a 50 day moving average price of $80.46 and a 200 day moving average price of $73.29. LivaNova PLC has a twelve month low of $48.82 and a twelve month high of $85.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. The firm has a market cap of $4.31 billion, a P/E ratio of 23.13 and a beta of 0.87.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.09 by $0.17. The company had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.05 earnings per share. Research analysts forecast that LivaNova PLC will post 3.77 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Mizuho raised their target price on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Zacks Research cut LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a report on Wednesday, August 5th. Freedom Capital raised LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Finally, KeyCorp increased their target price on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Six analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.12.

Insider Activity at LivaNova

In related news, Director Brooke Story sold 2,300 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the sale, the director owned 7,488 shares in the company, valued at $609,672.96. This represents a 23.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Francesco Bianchi sold 1,650 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $79.72, for a total value of $131,538.00. Following the completion of the sale, the director directly owned 7,934 shares of the company’s stock, valued at $632,498.48. This represents a 17.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.35% of the stock is owned by corporate insiders.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.